Cargando…
A proteomic network approach resolves stage-specific molecular phenotypes in chronic traumatic encephalopathy
BACKGROUND: There is an association between repetitive head injury (RHI) and a pathologic diagnosis of chronic traumatic encephalopathy (CTE) characterized by the aggregation of proteins including tau. The underlying molecular events that cause these abnormal protein accumulations remain unclear. He...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235576/ https://www.ncbi.nlm.nih.gov/pubmed/34172091 http://dx.doi.org/10.1186/s13024-021-00462-3 |
_version_ | 1783714351755034624 |
---|---|
author | Gutierrez-Quiceno, Laura Dammer, Eric B. Johnson, Ashlyn Grace Webster, James A. Shah, Rhythm Duong, Duc Yin, Luming Seyfried, Nicholas T. Alvarez, Victor E. Stein, Thor D. McKee, Ann C. Hales, Chadwick M. |
author_facet | Gutierrez-Quiceno, Laura Dammer, Eric B. Johnson, Ashlyn Grace Webster, James A. Shah, Rhythm Duong, Duc Yin, Luming Seyfried, Nicholas T. Alvarez, Victor E. Stein, Thor D. McKee, Ann C. Hales, Chadwick M. |
author_sort | Gutierrez-Quiceno, Laura |
collection | PubMed |
description | BACKGROUND: There is an association between repetitive head injury (RHI) and a pathologic diagnosis of chronic traumatic encephalopathy (CTE) characterized by the aggregation of proteins including tau. The underlying molecular events that cause these abnormal protein accumulations remain unclear. Here, we hypothesized that identifying the human brain proteome from serial CTE stages (CTE I-IV) would provide critical new insights into CTE pathogenesis. Brain samples from frontotemporal lobar degeneration due to microtubule associated protein tau (FTLD-MAPT) mutations were also included as a distinct tauopathy phenotype for comparison. METHODS: Isobaric tandem mass tagged labeling and mass spectrometry (TMT-MS) followed by integrated differential and co-expression analysis (i.e., weighted gene co-expression network analysis (WGCNA)) was used to define modules of highly correlated proteins associated with clinical and pathological phenotypes in control (n = 23), CTE (n = 43), and FTLD-MAPT (n = 12) post-mortem cortical tissues. We also compared these findings to network analysis of AD brain. RESULTS: We identified over 6000 unique proteins across all four CTE stages which sorted into 28 WGCNA modules. Consistent with Alzheimer’s disease, specific modules demonstrated reduced neuronal protein levels, suggesting a neurodegeneration phenotype, while other modules were increased, including proteins associated with inflammation and glial cell proliferation. Notably, unique CTE-specific modules demonstrated prominent enrichment of immunoglobulins, including IGHM and IGLL5, and extracellular matrix (ECM) proteins as well as progressive protein changes with increasing CTE pathologic stage. Finally, aggregate cell subtype (i.e., neurons, microglia, astrocytes) protein abundance levels in CTE cases were similar in expression to AD, but at intermediate levels between controls and the more exaggerated phenotype of FTLD-MAPT, especially in astrocytes. CONCLUSIONS: Overall, we identified thousands of protein changes in CTE postmortem brain and demonstrated that CTE has a pattern of neurodegeneration in neuronal-synaptic and inflammation modules similar to AD. We also identified unique CTE progressive changes, including the enrichment of immunoglobulins and ECM proteins even in early CTE stages. Early and sustained changes in astrocyte modules were also observed. Overall, the prominent overlap with FTLD-MAPT cases confirmed that CTE is on the tauopathy continuum and identified CTE stage specific molecular phenotypes that provide novel insights into disease pathogenesis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13024-021-00462-3. |
format | Online Article Text |
id | pubmed-8235576 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-82355762021-06-28 A proteomic network approach resolves stage-specific molecular phenotypes in chronic traumatic encephalopathy Gutierrez-Quiceno, Laura Dammer, Eric B. Johnson, Ashlyn Grace Webster, James A. Shah, Rhythm Duong, Duc Yin, Luming Seyfried, Nicholas T. Alvarez, Victor E. Stein, Thor D. McKee, Ann C. Hales, Chadwick M. Mol Neurodegener Research Article BACKGROUND: There is an association between repetitive head injury (RHI) and a pathologic diagnosis of chronic traumatic encephalopathy (CTE) characterized by the aggregation of proteins including tau. The underlying molecular events that cause these abnormal protein accumulations remain unclear. Here, we hypothesized that identifying the human brain proteome from serial CTE stages (CTE I-IV) would provide critical new insights into CTE pathogenesis. Brain samples from frontotemporal lobar degeneration due to microtubule associated protein tau (FTLD-MAPT) mutations were also included as a distinct tauopathy phenotype for comparison. METHODS: Isobaric tandem mass tagged labeling and mass spectrometry (TMT-MS) followed by integrated differential and co-expression analysis (i.e., weighted gene co-expression network analysis (WGCNA)) was used to define modules of highly correlated proteins associated with clinical and pathological phenotypes in control (n = 23), CTE (n = 43), and FTLD-MAPT (n = 12) post-mortem cortical tissues. We also compared these findings to network analysis of AD brain. RESULTS: We identified over 6000 unique proteins across all four CTE stages which sorted into 28 WGCNA modules. Consistent with Alzheimer’s disease, specific modules demonstrated reduced neuronal protein levels, suggesting a neurodegeneration phenotype, while other modules were increased, including proteins associated with inflammation and glial cell proliferation. Notably, unique CTE-specific modules demonstrated prominent enrichment of immunoglobulins, including IGHM and IGLL5, and extracellular matrix (ECM) proteins as well as progressive protein changes with increasing CTE pathologic stage. Finally, aggregate cell subtype (i.e., neurons, microglia, astrocytes) protein abundance levels in CTE cases were similar in expression to AD, but at intermediate levels between controls and the more exaggerated phenotype of FTLD-MAPT, especially in astrocytes. CONCLUSIONS: Overall, we identified thousands of protein changes in CTE postmortem brain and demonstrated that CTE has a pattern of neurodegeneration in neuronal-synaptic and inflammation modules similar to AD. We also identified unique CTE progressive changes, including the enrichment of immunoglobulins and ECM proteins even in early CTE stages. Early and sustained changes in astrocyte modules were also observed. Overall, the prominent overlap with FTLD-MAPT cases confirmed that CTE is on the tauopathy continuum and identified CTE stage specific molecular phenotypes that provide novel insights into disease pathogenesis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13024-021-00462-3. BioMed Central 2021-06-25 /pmc/articles/PMC8235576/ /pubmed/34172091 http://dx.doi.org/10.1186/s13024-021-00462-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Gutierrez-Quiceno, Laura Dammer, Eric B. Johnson, Ashlyn Grace Webster, James A. Shah, Rhythm Duong, Duc Yin, Luming Seyfried, Nicholas T. Alvarez, Victor E. Stein, Thor D. McKee, Ann C. Hales, Chadwick M. A proteomic network approach resolves stage-specific molecular phenotypes in chronic traumatic encephalopathy |
title | A proteomic network approach resolves stage-specific molecular phenotypes in chronic traumatic encephalopathy |
title_full | A proteomic network approach resolves stage-specific molecular phenotypes in chronic traumatic encephalopathy |
title_fullStr | A proteomic network approach resolves stage-specific molecular phenotypes in chronic traumatic encephalopathy |
title_full_unstemmed | A proteomic network approach resolves stage-specific molecular phenotypes in chronic traumatic encephalopathy |
title_short | A proteomic network approach resolves stage-specific molecular phenotypes in chronic traumatic encephalopathy |
title_sort | proteomic network approach resolves stage-specific molecular phenotypes in chronic traumatic encephalopathy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235576/ https://www.ncbi.nlm.nih.gov/pubmed/34172091 http://dx.doi.org/10.1186/s13024-021-00462-3 |
work_keys_str_mv | AT gutierrezquicenolaura aproteomicnetworkapproachresolvesstagespecificmolecularphenotypesinchronictraumaticencephalopathy AT dammerericb aproteomicnetworkapproachresolvesstagespecificmolecularphenotypesinchronictraumaticencephalopathy AT johnsonashlyngrace aproteomicnetworkapproachresolvesstagespecificmolecularphenotypesinchronictraumaticencephalopathy AT websterjamesa aproteomicnetworkapproachresolvesstagespecificmolecularphenotypesinchronictraumaticencephalopathy AT shahrhythm aproteomicnetworkapproachresolvesstagespecificmolecularphenotypesinchronictraumaticencephalopathy AT duongduc aproteomicnetworkapproachresolvesstagespecificmolecularphenotypesinchronictraumaticencephalopathy AT yinluming aproteomicnetworkapproachresolvesstagespecificmolecularphenotypesinchronictraumaticencephalopathy AT seyfriednicholast aproteomicnetworkapproachresolvesstagespecificmolecularphenotypesinchronictraumaticencephalopathy AT alvarezvictore aproteomicnetworkapproachresolvesstagespecificmolecularphenotypesinchronictraumaticencephalopathy AT steinthord aproteomicnetworkapproachresolvesstagespecificmolecularphenotypesinchronictraumaticencephalopathy AT mckeeannc aproteomicnetworkapproachresolvesstagespecificmolecularphenotypesinchronictraumaticencephalopathy AT haleschadwickm aproteomicnetworkapproachresolvesstagespecificmolecularphenotypesinchronictraumaticencephalopathy AT gutierrezquicenolaura proteomicnetworkapproachresolvesstagespecificmolecularphenotypesinchronictraumaticencephalopathy AT dammerericb proteomicnetworkapproachresolvesstagespecificmolecularphenotypesinchronictraumaticencephalopathy AT johnsonashlyngrace proteomicnetworkapproachresolvesstagespecificmolecularphenotypesinchronictraumaticencephalopathy AT websterjamesa proteomicnetworkapproachresolvesstagespecificmolecularphenotypesinchronictraumaticencephalopathy AT shahrhythm proteomicnetworkapproachresolvesstagespecificmolecularphenotypesinchronictraumaticencephalopathy AT duongduc proteomicnetworkapproachresolvesstagespecificmolecularphenotypesinchronictraumaticencephalopathy AT yinluming proteomicnetworkapproachresolvesstagespecificmolecularphenotypesinchronictraumaticencephalopathy AT seyfriednicholast proteomicnetworkapproachresolvesstagespecificmolecularphenotypesinchronictraumaticencephalopathy AT alvarezvictore proteomicnetworkapproachresolvesstagespecificmolecularphenotypesinchronictraumaticencephalopathy AT steinthord proteomicnetworkapproachresolvesstagespecificmolecularphenotypesinchronictraumaticencephalopathy AT mckeeannc proteomicnetworkapproachresolvesstagespecificmolecularphenotypesinchronictraumaticencephalopathy AT haleschadwickm proteomicnetworkapproachresolvesstagespecificmolecularphenotypesinchronictraumaticencephalopathy |